To evaluate the role of abatacept in the treatment of rheumatoid arthritis (RA) with respect to its pharmacology, pharmacokinetics, clinical efficacy, and adverse effect profile.
Data Sources:
A MEDLINE search (1966–November 2006) was conducted for primary and secondary literature. Search terms included BL125118, CTLA4-Ig, abatacept, and rheumatoid arthritis.
Study Selection and Data Extraction:
All articles retrieved from the data sources were evaluated. The most relevant studies were selected and included in this review.
Data Synthesis:
Abatacept is the first in a new class of RA agents with a unique mechanism of action. It is a selective costimulation modulator that inhibits T cell activation and other inflammatory mediators. This agent has been studied as an adjunct in patients who are receiving disease-modifying antirheumatic drug therapy and in those who have failed tumor necrosis factor-alfa antagonist therapy. Clinical trials were evaluated for information on abatacept's indication, dosing, safety, and efficacy profile.
Conclusions:
Abatacept has been shown to reduce signs and symptoms of RA and improve the condition of patients with moderately to severely active RA.
Get full access to this article
View all access options for this article.
References
1.
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum2002; 46: 328–46.
2.
CooperNJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology (Oxford)2000; 39: 28–33.
3.
SokkaT. Work disability in rheumatoid arthritis. Clin Exp Rheum2003; 21 (suppl): S71–4.
4.
ScottDLSymmonsDPCoultonBLPopertAJ. Long-term outcomes of treating RA: Results after 20 years. Lancet1987; 1: 1108–11.
5.
RindfleischJAMullerD. Diagnosis and management of rheumatoid arthritis. Am Fam Phys2005; 72: 1037–47.
6.
MikulsTRCerhanJRCriswellLA, Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa Women's Health Study. Arthritis Rheum2002; 46: 83–91.
7.
WeyandCMMcCarthyTGGoronzyJJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest1995; 95: 2120–6.
8.
GoldringSR. A 55-year-old woman with rheumatoid arthritis. JAMA2000; 283: 524–31.
9.
PanayiGSCorrigallVMPitzalisC. Pathogenesis of rheumatoid arthritis: The role of T cells and other beasts. Rheum Dis Clin North Am2001; 27: 317–34.
10.
KremerJM. Selective costimulation modulators: A novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol2005; 11 (3 Suppl): S55–62.
11.
RudermanEMPopeRM. The evolving clinical profile of abatacept (CTLA4-Ig): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Ther2005; 7 (suppl): S21–5.
12.
MackieSLVitalEMPonchelFEmeryP. Co-stimulatory blockade as therapy for rheumatoid arthritis. Curr Rheum Rep2005; 7: 400–6.
13.
AbramowiczM.Drugs for rheumatoid arthritis. Treatment guidelines. Med Lett2005; 40: 83–90.
14.
VollREKaldenJR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?Ann N Y Acad Sci2005; 1051: 799–810.
15.
Package insert. Orencia (abatacept). Princeton, NJ: Bristol-Myers Squibb, December 2005.
16.
FelsonDTAndersonJJBoersM, American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum1995; 38: 727–35.
17.
ArnettFCEdworthySMBlochDA, The American Rheumatism Association criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988; 31: 315–24.
18.
DavisJCKlaresksogLWesthovensR. Selective costimulation modulators: Addressing unmet needs in rheumatoid arthritis management. Medscape Gen Med2004; 6: 1.
19.
MalmstromVTrollmoCKlareskogL.Modulating co-stimulation: A rational strategy in the treatment of rheumatoid arthritis?Arthritis Res Ther2005; 7 (suppl 2): S15–20.
20.
SrinivasNRWeinerRSWarnerG, Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J Pharm Sci1996; 85: 1–4.
21.
AbramsJRLebwohlMGGuzzoCA, CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest1999; 103: 1243–52.
22.
MorelandLWAltenRVan den BoschF, Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA4-Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum2002; 46: 1470–9.
23.
WeinblattMSchiffMGoldmanM, A pilot, multi-center, randomized, double-blind, placebo controlled of a co-stimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis (abstract). Arthritis Rheum2002; 46: S204.
24.
KremerJDougadosMEmeryP, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept. Arthritis Rheum2005; 52: 2263–71.
25.
KremerJMWesthovensRLeonM, Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med2003; 349: 1907–15.
26.
GenoveseMCBeckerJCSchiffM, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med2005; 353: 1114–23.
27.
WellsGATugwellPKraagGRBakerPRGrohJRedelmeierDA. Minimum important difference between patients with rheumatoid arthritis: The patient's perspective. J Rheumatol1993; 20: 557–60.
28.
RiesLAGEisnerMPKosaryCL, eds. SEER cancer statistics review, 1975–2001, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2001 (accessed 2006 Mar 25).
